Retatrutide 12mg: Maximum Dose — Peak Results
Retatrutide 12mg is the maximum dose studied in Phase 2 trials and produced the headline-making results: 24.2% average body weight loss in 48 weeks, with the weight loss curve still declining at study end (Jastreboff et al., NEJM 2023). At this dose, all three receptor activations are maximized — GLP-1, GIP, and glucagon work at full intensity. The 12mg dose represents the current ceiling of pharmacological weight loss, approaching and potentially matching bariatric surgery outcomes.
Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. The 12mg dose has the highest side effect rates and should only be used under medical supervision. Always consult a qualified healthcare provider.
The Record-Setting Results
| Metric | Retatrutide 12mg |
|---|---|
| Average weight loss (48 wks) | 24.2% |
| Rate of loss | ~2.0% per month |
| Lost >20% body weight | ~63% |
| Lost >25% body weight | ~45% |
| Plateau reached? | No — still declining at 48 weeks |
| Projected at 72 weeks | Potentially 28%+ |
No Plateau: What the Curve Tells Us
Perhaps the most remarkable finding at 12mg is that weight loss was still accelerating at 48 weeks. Every other weight loss drug shows a plateau where weight stabilizes despite continued treatment. Retatrutide's weight loss curve was still declining, suggesting that longer treatment could produce 28% or more total weight loss. Phase 3 TRIUMPH trials with 72-week endpoints will reveal the true ceiling.
This ongoing trajectory is likely driven by the glucagon component. While the GLP-1-mediated appetite effects may plateau as the body adapts, glucagon-driven energy expenditure and fat oxidation continue. The dual-mechanism approach (reducing intake AND increasing expenditure) may prevent the plateaus seen with intake-only drugs.
Side Effects at Maximum Dose
- Nausea: 26% — notable that this is lower than semaglutide despite greater efficacy
- Diarrhea: 22%
- Vomiting: 13%
- Constipation: 14%
- Dysesthesia: 20.9% — the highest of any dose; most common side effect unique to retatrutide
- Heart rate: 2-4 bpm increase
- Discontinuation: ~6% — remarkably low for a drug this potent
Who Needs 12mg?
- Highest BMI patients: Starting BMI above 40 may require maximum dosing for adequate results
- Fatty liver disease: Maximum glucagon activation provides the greatest hepatic fat reduction
- Patients who plateau at 8mg: The additional 1.4 percentage points can be meaningful
- Patients with excellent tolerance: If 8mg side effects are minimal, 12mg is a reasonable step
Who Should Stay at 8mg
- Patients with significant dysesthesia at 8mg (it will worsen at 12mg)
- Patients achieving satisfactory weight loss at 8mg (22.8% is excellent)
- Patients with cardiovascular concerns about additional heart rate increase
- Patients who prefer the lowest effective dose for long-term treatment
Real-World Translation: What 24.2% Means
For a 300-pound person, 24.2% weight loss is approximately 73 pounds. For a 250-pound person, it is about 60 pounds. This level of weight loss typically resolves or dramatically improves type 2 diabetes, sleep apnea, hypertension, fatty liver disease, joint pain, and cardiovascular risk. It is life-changing weight loss from a weekly injection.
Start Losing Weight Now
Retatrutide 12mg is not yet available, but current medications already produce impressive results. Trimi offers compounded semaglutide at $99/month and compounded tirzepatide at $125/month. Tirzepatide produces 22.5% average weight loss — just 1.7 points less than retatrutide 12mg. Start today rather than waiting. Get started with Trimi.
Frequently Asked Questions
Is 12mg the maximum dose of retatrutide?
12mg was the highest dose studied in Phase 2. Phase 3 trials are studying the same dose range. Whether higher doses would be more effective is unknown — the risk-benefit ratio may not favor doses above 12mg.
How much weight can I lose on retatrutide 12mg?
The average is 24.2% in 48 weeks, with the potential for 28%+ with continued treatment. Individual results vary — some patients may lose more, others less.
Is 12mg safe?
Phase 2 data showed a 6% discontinuation rate due to adverse events at 12mg — comparable to lower doses and other GLP-1 medications. No serious safety signals were identified. Phase 3 data will provide more comprehensive long-term safety information.
Can I stay on 12mg long-term?
Long-term data is pending from Phase 3 trials. Based on the safety profile of similar medications, long-term use at the maintenance dose is anticipated to be the standard approach.
More on Retatrutide
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).